Aurobindo Pharma working on COVID-19 vaccine; shortlisted for BIRAC funding

In November 2019, Aurobindo Pharma said its subsidiary Auro Vaccines LLC entered into a pact to acquire certain business assets from Profectus BioSciences Inc USA for an upfront cash consideration of USD 11.29 million (around Rs 80 crore) with potential earn-outs on achieving certain milestones.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3a0OGxk
via IFTTT